View DividendPsyence Group マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間2.5yrs経営陣の近況お知らせ • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.お知らせ • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.お知らせ • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.お知らせ • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.お知らせ • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.お知らせ • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.すべての更新を表示Recent updatesお知らせ • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.お知らせ • Aug 23Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc.Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc on August 22, 2025. It is anticipated that the Acquisition will be completed by way of a three-corner amalgamation or similar transaction under the Business Corporations Act (Ontario), pursuant to which a wholly owned subsidiary of Psyence will amalgamate with Gold Coast Resources and each issued and outstanding common share of the Gold Coast Resources will be exchanged for one common share of the resulting issuer ("Resulting Issuer Share"). Convertible securities of the Gold Coast Resources will be exchanged on the same basis. The exchange ratio refers to post-consolidation shares of Psyence Group Inc., if applicable. Pursuant to the LOI, Psyence will advance a secured loan to GoldCoast bearing interest at 10% per annum, maturing on the earlier of the closing of the Acquisition and December 31, 2025, and secured against all assets of GoldCoast. The use of proceeds of the Loan will be for the preparation and submission of the application for the exploration license as well as the preparation of the NI 43-101 Qualified Persons report. The Acquisition is subject to execution of a definitive agreement, completion of satisfactory due diligence by each party, receipt of all required corporate, shareholder and regulatory approvals and other customary closing conditions. Following closing, the board of directors and senior management of the Resulting Issuer will be reconstituted to include nominees of Gold Coast Resources.お知らせ • Jun 19Psyence Group Inc. announced that it expects to receive CAD 0.6 million in fundingPsyence Group Inc. announces a non-brokered private placement to issue 6,000,000 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 600,000 on June 18, 2025. The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals. No finder’s fees or commissions will be payable in connection with the Offering. The Offering is expected to close on or about June 25, 2025.お知らせ • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.お知らせ • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.お知らせ • Mar 27An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).An undisclosed buyer entered into a conditional agreement to acquire Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) for CAD 1 million on March 11, 2024. The transaction is approved by the board and is subjected to certain closing conditions.An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) on March 26, 2024. Psyence is pleased that the conditions to implement the transaction have been met.お知らせ • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.お知らせ • Oct 31Psyence Group Inc. announced that it has received CAD 0.162697 million in fundingPsyence Group Inc. announced a private placement of 1,355,810 common shares at a price of CAD 0.12 per unit for the gross proceeds of CAD 162,697 on October 30, 2023. The transaction included participation from returning individual investors, Brandon Kerzner and Cody Futeran. As a part of the transaction, the company also issued 2,467 common shares at a price of CAD 0.12 per common share as payment of a finder's fee of CAD 296.お知らせ • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.お知らせ • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.お知らせ • Jan 24Psyence Group Inc., Annual General Meeting, Mar 09, 2023Psyence Group Inc., Annual General Meeting, Mar 09, 2023.CEOPsyence Group CEOがいない、あるいは彼らに関するデータがない。取締役名称ポジション在職期間報酬所有権Jody AufrichtigCo-Founder & Executive Chairman5.1yrsCA$150.00k0.74% $ 10.2kAlan FriedmanCapital Markets Advisor & Directorless than a yearデータなし1.11% $ 15.2kWarwick Corden-LloydDirector1.9yrsCA$150.00k0.64% $ 8.7kAC BraddockMember of Scientific Advisory Board3.1yrsデータなしデータなしもっと見る2.5yrs平均在職期間51yo平均年齢経験豊富なボード: PSYG.Fの 取締役会 は 経験豊富 ではない ( 2.5年の平均在任期間) ため、新しい取締役会が必要であると考えられます。View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/07 23:31終値2025/11/10 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Psyence Group Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ryan HamptonHannam & Partners (Advisory) LLP
お知らせ • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.
お知らせ • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.
お知らせ • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.
お知らせ • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.
お知らせ • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.
お知らせ • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.
お知らせ • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.
お知らせ • Aug 23Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc.Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc on August 22, 2025. It is anticipated that the Acquisition will be completed by way of a three-corner amalgamation or similar transaction under the Business Corporations Act (Ontario), pursuant to which a wholly owned subsidiary of Psyence will amalgamate with Gold Coast Resources and each issued and outstanding common share of the Gold Coast Resources will be exchanged for one common share of the resulting issuer ("Resulting Issuer Share"). Convertible securities of the Gold Coast Resources will be exchanged on the same basis. The exchange ratio refers to post-consolidation shares of Psyence Group Inc., if applicable. Pursuant to the LOI, Psyence will advance a secured loan to GoldCoast bearing interest at 10% per annum, maturing on the earlier of the closing of the Acquisition and December 31, 2025, and secured against all assets of GoldCoast. The use of proceeds of the Loan will be for the preparation and submission of the application for the exploration license as well as the preparation of the NI 43-101 Qualified Persons report. The Acquisition is subject to execution of a definitive agreement, completion of satisfactory due diligence by each party, receipt of all required corporate, shareholder and regulatory approvals and other customary closing conditions. Following closing, the board of directors and senior management of the Resulting Issuer will be reconstituted to include nominees of Gold Coast Resources.
お知らせ • Jun 19Psyence Group Inc. announced that it expects to receive CAD 0.6 million in fundingPsyence Group Inc. announces a non-brokered private placement to issue 6,000,000 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 600,000 on June 18, 2025. The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals. No finder’s fees or commissions will be payable in connection with the Offering. The Offering is expected to close on or about June 25, 2025.
お知らせ • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.
お知らせ • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.
お知らせ • Mar 27An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).An undisclosed buyer entered into a conditional agreement to acquire Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) for CAD 1 million on March 11, 2024. The transaction is approved by the board and is subjected to certain closing conditions.An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) on March 26, 2024. Psyence is pleased that the conditions to implement the transaction have been met.
お知らせ • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.
お知らせ • Oct 31Psyence Group Inc. announced that it has received CAD 0.162697 million in fundingPsyence Group Inc. announced a private placement of 1,355,810 common shares at a price of CAD 0.12 per unit for the gross proceeds of CAD 162,697 on October 30, 2023. The transaction included participation from returning individual investors, Brandon Kerzner and Cody Futeran. As a part of the transaction, the company also issued 2,467 common shares at a price of CAD 0.12 per common share as payment of a finder's fee of CAD 296.
お知らせ • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.
お知らせ • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.
お知らせ • Jan 24Psyence Group Inc., Annual General Meeting, Mar 09, 2023Psyence Group Inc., Annual General Meeting, Mar 09, 2023.